In one post you claim that single agent mTORS don't work then in the next you claim that they do (just not ariads according to you). Make up your mind. The fact is that we know single-agent mTORs do work - just last week Afinitor (Novartis' Mtor) met its primary endpoint in a study of patients with advanced pancreatic neuroendocrine tumors.
It's rather disingenuous to claim that somehow having the trial continue to it's endpoint is anything but positive. Unlike rida's P2 where 90% of pts were progressing, the SUCCEED trial enrolled pts who were disease stable so it's really not all that surprising that it's going to take longer for the arm to diverge. Either way we'll know soon enough.
Again, please feel free to point me to any results that support your claim that there are other therapies farther along than rida that will work better in Sarcoma in a maintenance setting. I guess you now realize that despite your earlier claim to the contrary, ZIOP ain't one of them.
News 
Market Data 
Discover 
